MSLN and ovarian carcinoma: Interestingly, a clinical study conducted in patients with MSLN-positive drug-resistant, relapsed ovarian cancer showed differences in metabolic profiles between patients with high or low response to an anti-MSLN CAR-T therapy (known as LD013) (NCT05372692) (Table 1).